FPPS inhibitor
Farnesyl pyrophosphate synthase inhibitor
- Mevalonate-pathway block in osteoclasts
- Impaired prenylation disables osteoclasts → ↓ bone resorption
- Suppressed bone turnover → osteonecrosis of the jaw, atypical femoral fractures
- Blocks the mevalonate pathway in osteoclasts — the bisphosphonates
- Acute phase reaction with IV dosing
- Osteonecrosis of the jaw and atypical femoral fracture with long use
Drugs with this mechanism (4)
- Alendronate — Oral bisphosphonate for osteoporosis; upright dosing to avoid esophagitis.
- Ibandronate — Nitrogen-containing bisphosphonate; monthly oral or quarterly IV.
- Risedronate — Oral bisphosphonate for osteoporosis.
- Zoledronic acid — Potent IV bisphosphonate given yearly for osteoporosis; acute-phase reaction.
All mechanisms · Open FPPS inhibitor in the interactive console ↗